Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 18/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.81 |
| ▸ | HTT | P42858 | 3/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.81 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.81 |
| ▸ | TP53 | P04637 | 2/20 | 0.81 |
| ▸ | SLC27A2 | O14975 | 1/20 | 0.69 |
| ▸ | XBP1 | P17861 | 1/20 | 0.68 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.68 |
| ▸ | MMP12 | P39900 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4345668 | 0.89 | ADAMTS5 (1.00) | ADAMTS5SMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL22571291 | 0.89 | ADAMTS5 (0.81) | ADAMTS5SMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL4354514 | 0.88 | ADAMTS5 (0.81) | ADAMTS5SMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL22571283 | 0.88 | ADAMTS5 (0.78) | ADAMTS5SMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL4983114 | 0.86 | ADAMTS5 (0.78) | ADAMTS5SMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL4347482 | 0.86 | ADAMTS5 (1.00) | ADAMTS5SMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL4985762 | 0.86 | ADAMTS5 (0.79) | ADAMTS5SMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL6273051 | 0.85 | SMN1; SMN2 (0.76) | ADAMTS5SMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL4354096 | 0.84 | ADAMTS5 (1.00) | ADAMTS5SMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL15614739 | 0.82 | SMN1; SMN2 (1.00) | ADAMTS5SMN1; SMN2HPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032584-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | Wyeth (US) | 2009-03-11 | — | — | EP | claimed |
| US-20080125469-A1 | Thiadiazole compounds and methods of use thereof | WYETH (US) | 2008-05-29 | — | — | US | claimed |
| WO-2007146138-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WYETH (US) | 2007-12-21 | — | — | WO | claimed |
| WO-2005092304-A2 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2005-10-06 | — | — | WO | claimed |
| US-20220202785-A1 | SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-30 | — | — | US | disclosed |
| WO-2020214896-A1 | SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-10-22 | — | — | WO | disclosed |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10000511-B2 | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20150315211-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-20130035304-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2013-02-07 | — | — | US | disclosed |
| US-20080125469-A1 | Thiadiazole compounds and methods of use thereof | WYETH (US) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | ADAMTS5 2846/4885SMN1; SMN2 595/4885HPGD 268/4885 |
| US-20130035304-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | MCL1, BCL2, BCL2L1 | ADAMTS5 3338/4885SMN1; SMN2 2677/4885HPGD 2421/4885 |
| US-10000511-B2 | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | MCL1, BCL2, BCL2L1 | ADAMTS5 3338/4885SMN1; SMN2 2677/4885HPGD 2421/4885 |
| US-20150315211-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | MCL1, BCL2, BCL2L1 | ADAMTS5 3338/4885SMN1; SMN2 2677/4885HPGD 2421/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | ADAMTS5 2710/4885SMN1; SMN2 839/4885HPGD 236/4885 |
| US-20220202785-A1 | SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS | GPR68, GPR65, GPR4 | ADAMTS5 3017/4885SMN1; SMN2 991/4885HPGD 2490/4885 |
| US-20080125469-A1 | Thiadiazole compounds and methods of use thereof | ADAMTS5, ADAMTS1, TIMP3 | ADAMTS5 1/4885SMN1; SMN2 876/4885HPGD 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.